. . . . . . . . . . "Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (C_max) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses. "@en . . . "Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities."@en . "Revlimid"@en . . "CC-5013"@en . . . "approved"@en . . . . "Healthy subjects = 3 hours; Multiple myeloma or MDS patients = 3 - 5 hours. "@en . "CDC 501"@en . . . "191732-72-6"@en . "The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity"@en . . "Elimination is primarily renal. When a single oral dose of 25 mg is given healthy subjects, 90% and 4% of the dose is eliminated in urine and feces, respectively. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively."@en . . . . . . "IMid-1"@en . . . "Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Rajasekhar Kadaboina, Veerender Murki, Amarendhar Manda, Venkata Rao Badisa, Naresh Vemula, Rama Seshagiri Rao Pulla, Venu Nalivela, \"PREPARATION OF LENALIDOMIDE.\" U.S. Patent US20110021567, issued January 27, 2011."@en . . . . . . . . . . "Lenalidomide"@en . . . . . . . . "1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline"@en . "3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione"@en . . "30% protein bound. "@en . . . . . . . . "IMiD3"@en . . . . "Humans and other mammals"@en . . . "# List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15703420 # Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16569772 # Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16344099"@en . . "The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions."@en . " "@en . . "Lenalidomide (initially known as CC-5013 and marketed as Revlimid\u00AE by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005. "@en . . . "The renal clearance of lenalidomide exceeds the glomerular filtration rate. "@en . . . "When given with a fatty meal, the extent of absorption is reduced."@en . . .